Literature DB >> 18949012

Reovirus infection of cancer cells is not due to activated Ras pathway.

L Song, T Ohnuma, I H Gelman, J F Holland.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18949012     DOI： 10.1038/cgt.2008.84

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN： 0929-1903            Impact factor:   5.987


× No keyword cloud information.
  11 in total

1.  The viral tropism of two distinct oncolytic viruses, reovirus and myxoma virus, is modulated by cellular tumor suppressor gene status.

Authors:  M Kim; C T Williamson; J Prudhomme; D G Bebb; K Riabowol; P W K Lee; S P Lees-Miller; Y Mori; M M Rahman; G McFadden; R N Johnston
Journal:  Oncogene       Date:  2010-05-17       Impact factor: 9.867

2.  Activity levels of cathepsins B and L in tumor cells are a biomarker for efficacy of reovirus-mediated tumor cell killing.

Authors:  Y Terasawa; T Hotani; Y Katayama; M Tachibana; H Mizuguchi; F Sakurai
Journal:  Cancer Gene Ther       Date:  2015-01-30       Impact factor: 5.987

Review 3.  Clinical development of reovirus for cancer therapy: An oncolytic virus with immune-mediated antitumor activity.

Authors:  Jun Gong; Esha Sachdev; Alain C Mita; Monica M Mita
Journal:  World J Methodol       Date:  2016-03-26

4.  Noncanonical Cell Death Induction by Reassortant Reovirus.

Authors:  Roxana M Rodríguez Stewart; Vishnu Raghuram; Jameson T L Berry; Gaurav N Joshi; Bernardo A Mainou
Journal:  J Virol       Date:  2020-10-27       Impact factor: 5.103

5.  Pro-inflammatory cytokine/chemokine production by reovirus treated melanoma cells is PKR/NF-κB mediated and supports innate and adaptive anti-tumour immune priming.

Authors:  Lynette Steele; Fiona Errington; Robin Prestwich; Elizabeth Ilett; Kevin Harrington; Hardev Pandha; Matt Coffey; Peter Selby; Richard Vile; Alan Melcher
Journal:  Mol Cancer       Date:  2011-02-21       Impact factor: 27.401

6.  Junctional adhesion molecule-A is overexpressed in advanced multiple myeloma and determines response to oncolytic reovirus.

Authors:  Kevin R Kelly; Claudia M Espitia; Weiguo Zhao; Erik Wendlandt; Guido Tricot; Fenghuang Zhan; Jennifer S Carew; Steffan T Nawrocki
Journal:  Oncotarget       Date:  2015-12-01

Review 7.  Oncolytic virotherapy as an immunotherapeutic strategy for multiple myeloma.

Authors:  Daniel E Meyers; Satbir Thakur; Chandini M Thirukkumaran; Don G Morris
Journal:  Blood Cancer J       Date:  2017-12-05       Impact factor: 11.037

Review 8.  Current understanding of reovirus oncolysis mechanisms.

Authors:  Matthew B Phillips; Johnasha D Stuart; Roxana M Rodríguez Stewart; Jameson Tl Berry; Bernardo A Mainou; Karl W Boehme
Journal:  Oncolytic Virother       Date:  2018-06-14

Review 9.  Activated ras signaling pathways and reovirus oncolysis: an update on the mechanism of preferential reovirus replication in cancer cells.

Authors:  Jun Gong; Monica M Mita
Journal:  Front Oncol       Date:  2014-06-26       Impact factor: 6.244

Review 10.  Oncolytic Viruses for Multiple Myeloma Therapy.

Authors:  Christine M Calton; Kevin R Kelly; Faiz Anwer; Jennifer S Carew; Steffan T Nawrocki
Journal:  Cancers (Basel)       Date:  2018-06-14       Impact factor: 6.639
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.